|
G |
Abcd2 |
ATP binding cassette subfamily D member 2 |
increases expression |
ISO |
MK-886 results in increased expression of ABCD2 mRNA |
CTD |
PMID:18292206 |
|
NCBI chr 7:122,263,034...122,311,642
Ensembl chr 7:122,263,032...122,311,642
|
|
G |
Acmsd |
aminocarboxymuconate semialdehyde decarboxylase |
multiple interactions |
EXP |
MK-886 inhibits the reaction [pirinixic acid results in decreased expression of ACMSD mRNA] |
CTD |
PMID:18320257 |
|
NCBI chr13:39,200,486...39,244,337
Ensembl chr13:39,200,314...39,245,209
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions increases expression |
EXP ISO |
MK-886 inhibits the reaction [pirinixic acid results in increased expression of ACOX1 mRNA] MK-886 results in increased expression of ACOX1 mRNA |
CTD |
PMID:18292206 PMID:18320257 |
|
NCBI chr10:101,406,197...101,431,242
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Arsenic Trioxide results in increased expression of ACTA2 protein] |
CTD |
PMID:30677399 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions decreases activity |
ISO EXP |
MK-886 inhibits the reaction [ALOX5 protein results in increased metabolism of Hydroxyeicosatetraenoic Acids metabolite]; MK-886 inhibits the reaction [Nicotine results in increased expression of ALOX5 protein] MK-886 results in decreased activity of ALOX5 protein EPHX2 gene mutant form promotes the reaction [MK-886 inhibits the reaction [Lipopolysaccharides results in increased expression of ALOX5 protein]]; MK-886 inhibits the reaction [Lipopolysaccharides results in increased expression of ALOX5 protein] |
CTD |
PMID:9445378 PMID:11861792 PMID:14726295 PMID:19896470 PMID:20061081 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
multiple interactions decreases activity |
ISO EXP |
[MK-886 results in decreased activity of ALOX5AP protein] which results in decreased abundance of Leukotriene C4; MK-886 binds to and results in decreased activity of ALOX5AP protein; MK-886 inhibits the reaction [ALOX5AP protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]] |
CTD |
PMID:7990266 PMID:8058773 PMID:8666909 PMID:9113110 PMID:9609743 PMID:9850156 PMID:12629151 More...
|
|
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions decreases expression |
ISO |
MK-886 inhibits the reaction [TNF protein results in decreased expression of APOA1 mRNA] MK-886 results in decreased expression of APOA1 protein |
CTD |
PMID:19883121 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Nicotine results in decreased expression of BAX protein] |
CTD |
PMID:20061081 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Nicotine results in increased expression of BCL2 protein] |
CTD |
PMID:20061081 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
MK-886 inhibits the reaction [Nicotine results in decreased expression of CASP3 protein] MK-886 results in increased activity of CASP3 protein |
CTD |
PMID:20061081 PMID:22308955 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 protein |
CTD |
PMID:22135674 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Nicotine results in increased expression of CCND1 mRNA]; MK-886 inhibits the reaction [Nicotine results in increased expression of CCND1 protein] |
CTD |
PMID:20061081 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Nicotine results in increased expression of CCNE1 protein] |
CTD |
PMID:20061081 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[MK-886 binds to and results in decreased activity of PPARA protein] inhibits the reaction [perfluorooctanoic acid results in decreased expression of CDH1 protein]; MK-886 inhibits the reaction [Nicotine results in decreased expression of CDH1 mRNA] |
CTD |
PMID:20061081 PMID:23978332 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[MK-886 binds to and results in decreased activity of PPARA protein] inhibits the reaction [perfluorooctanoic acid results in decreased expression of CTNNB1 protein] |
CTD |
PMID:23978332 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
MK-886 promotes the reaction [Dronabinol results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:25291031 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Nicotine results in increased expression of E2F1 protein] |
CTD |
PMID:20061081 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 protein |
CTD |
PMID:22135674 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions |
ISO |
EPHX2 gene mutant form promotes the reaction [[Lipopolysaccharides co-treated with MK-886] results in decreased abundance of 11,12-dihydroxyeicosatrienoic acid]; EPHX2 gene mutant form promotes the reaction [[Lipopolysaccharides co-treated with MK-886] results in decreased abundance of 14,15-dihydroxyeicosatrienoic acid]; EPHX2 gene mutant form promotes the reaction [MK-886 inhibits the reaction [Lipopolysaccharides results in increased abundance of 5-hydroxy-6,8,11,14-eicosatetraenoic acid]]; EPHX2 gene mutant form promotes the reaction [MK-886 inhibits the reaction [Lipopolysaccharides results in increased expression of ALOX5 protein]]; MK-886 promotes the reaction [EPHX2 gene mutant form results in decreased susceptibility to Lipopolysaccharides] |
CTD |
PMID:19896470 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
MK-886 inhibits the reaction [3-((O-6-deoxymannopyranosyl-1-2-O-(xylopyranosyl-1-3)arabinopyranosyl)oxy)-21-glucopyranosyloxy-20-hydroxydammar-24-en-19-al inhibits the reaction [Lipopolysaccharides results in increased activity of F3 protein]]; MK-886 inhibits the reaction [pirinixic acid inhibits the reaction [Lipopolysaccharides results in increased activity of F3 protein]] |
CTD |
PMID:17141290 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fa2h |
fatty acid 2-hydroxylase |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Dronabinol results in increased expression of FA2H mRNA]; MK-886 promotes the reaction [Dronabinol results in increased expression of FA2H mRNA] |
CTD |
PMID:23535410 PMID:25291031 |
|
NCBI chr19:39,312,904...39,364,153
Ensembl chr19:39,312,906...39,364,153
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Zymosan results in increased secretion of IL10 protein] |
CTD |
PMID:16313356 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
MK-886 promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:19896470 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
MK-886 inhibits the reaction [mangiferin results in increased activity of LPL protein]; MK-886 inhibits the reaction [mangiferin results in increased expression of LPL mRNA]; MK-886 inhibits the reaction [Plant Extracts results in increased activity of LPL protein]; MK-886 inhibits the reaction [Plant Extracts results in increased expression of LPL mRNA] |
CTD |
PMID:15975614 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Ltb4r |
leukotriene B4 receptor |
multiple interactions |
EXP |
MK-886 binds to and results in decreased activity of LTB4R protein; MK-886 inhibits the reaction [LTB4R protein results in increased susceptibility to Formaldehyde] |
CTD |
PMID:19835937 |
|
NCBI chr15:29,263,126...29,265,716
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Arsenic Trioxide results in increased cleavage of MAP1LC3B protein] |
CTD |
PMID:30677399 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mmp7 |
matrix metallopeptidase 7 |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Nicotine results in increased expression of MMP7 mRNA] |
CTD |
PMID:20061081 |
|
NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Nicotine results in increased expression of MMP9 mRNA] MK-886 inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of MMP9 protein] |
CTD |
PMID:19837106 PMID:20061081 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
[fulvestrant co-treated with MK-886] inhibits the reaction [resveratrol results in increased expression of NOS3 mRNA] |
CTD |
PMID:21791144 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Bezafibrate results in increased expression of PDK4 mRNA]; MK-886 inhibits the reaction [Bezafibrate results in increased expression of PDK4 protein] |
CTD |
PMID:19683050 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Histamine results in increased expression of PLA2G4A mRNA] |
CTD |
PMID:9609743 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Nicotine results in increased expression of PLAU mRNA] |
CTD |
PMID:20061081 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Nicotine results in increased expression of PLAUR mRNA] |
CTD |
PMID:20061081 |
|
NCBI chr 1:80,053,441...80,068,384
Ensembl chr 1:80,050,324...80,068,595
|
|
G |
Poli |
DNA polymerase iota |
decreases activity |
ISO |
MK-886 results in decreased activity of POLI protein |
CTD |
PMID:23305233 |
|
NCBI chr18:64,116,774...64,134,373
Ensembl chr18:64,116,774...64,163,418
|
|
G |
Polk |
DNA polymerase kappa |
decreases activity |
ISO |
MK-886 results in decreased activity of POLK protein |
CTD |
PMID:23305233 |
|
NCBI chr 2:27,822,228...27,882,331
Ensembl chr 2:27,822,679...27,882,313
|
|
G |
Polm |
DNA polymerase mu |
decreases activity |
ISO |
MK-886 results in decreased activity of POLM protein |
CTD |
PMID:23305233 |
|
NCBI chr14:80,707,075...80,716,677
Ensembl chr14:80,706,345...80,717,086
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions increases expression |
ISO EXP |
[MK-886 binds to and results in decreased activity of PPARA protein] inhibits the reaction [perfluorooctanoic acid results in decreased expression of CDH1 protein]; [MK-886 binds to and results in decreased activity of PPARA protein] inhibits the reaction [perfluorooctanoic acid results in decreased expression of CTNNB1 protein]; [MK-886 binds to and results in decreased activity of PPARA protein] which results in decreased susceptibility to perfluorooctanoic acid; MK-886 binds to and results in decreased activity of PPARA protein; MK-886 inhibits the reaction [Arsenic Trioxide results in increased expression of PPARA protein]; MK-886 inhibits the reaction [Bezafibrate results in increased expression of PPARA mRNA]; MK-886 inhibits the reaction [mangiferin results in increased activity of PPARA protein]; MK-886 inhibits the reaction [perfluorooctane sulfonic acid results in increased activity of PPARA protein]; MK-886 inhibits the reaction [perfluorooctanoic acid results in increased activity of PPARA protein]; MK-886 inhibits the reaction [Plant Extracts results in increased activity of PPARA protein]; MK-886 promotes the reaction [Dronabinol results in increased expression of PPARA mRNA] [MK-886 binds to and results in decreased activity of PPARA protein] which results in decreased susceptibility to palmidrol analog; MK-886 binds to and results in decreased activity of PPARA protein MK-886 binds to and results in decreased activity of PPARA protein; MK-886 inhibits the reaction [perfluorooctane sulfonic acid results in increased activity of PPARA protein]; MK-886 inhibits the reaction [perfluorooctanoic acid results in increased activity of PPARA protein] MK-886 results in increased expression of PPARA mRNA |
CTD |
PMID:15899809 PMID:15975614 PMID:17047030 PMID:17558434 PMID:18292206 PMID:18320257 PMID:19403796 PMID:19683050 PMID:19883121 PMID:23978332 PMID:25291031 PMID:30677399 More...
|
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression increases activity affects localization |
ISO |
[Indomethacin co-treated with MK-886] affects the localization of PPARG protein; Indomethacin promotes the reaction [MK-886 results in increased activity of PPARG protein] MK-886 results in increased expression of PPARG mRNA MK-886 affects the localization of PPARG protein |
CTD |
PMID:15899809 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptges |
prostaglandin E synthase |
decreases activity |
ISO |
MK-886 results in decreased activity of PTGES protein |
CTD |
PMID:20933508 PMID:25451575 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Nicotine results in increased expression of RB1 protein modified form] |
CTD |
PMID:20061081 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
MK-886 inhibits the reaction [pirinixic acid results in decreased phosphorylation of RELA protein] |
CTD |
PMID:17371993 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rxra |
retinoid X receptor alpha |
increases expression multiple interactions |
ISO |
MK-886 results in increased expression of RXRA mRNA [MK-886 co-treated with Indomethacin] results in increased expression of RXRA mRNA |
CTD |
PMID:15899809 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
S100b |
S100 calcium binding protein B |
multiple interactions |
EXP |
MK-886 inhibits the reaction [pirinixic acid affects the expression of S100B protein] |
CTD |
PMID:16863991 |
|
NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
|
|
G |
Selp |
selectin P |
multiple interactions |
ISO |
MK-886 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein] |
CTD |
PMID:11116075 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
MK-886 promotes the reaction [SOD2 gene mutant form results in decreased abundance of Adenosine Triphosphate]; MK-886 promotes the reaction [SOD2 gene mutant form results in increased abundance of Lactic Acid] |
CTD |
PMID:25362851 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tfdp1 |
transcription factor Dp-1 |
multiple interactions |
ISO |
MK-886 inhibits the reaction [Nicotine results in increased expression of TFDP1 protein] |
CTD |
PMID:20061081 |
|
NCBI chr16:76,162,040...76,200,871
Ensembl chr16:76,162,043...76,200,817
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[Ovalbumin co-treated with MK-886] results in increased expression of TNF protein; MK-886 inhibits the reaction [TNF protein results in decreased expression of APOA1 mRNA]; monascin inhibits the reaction [[Ovalbumin co-treated with MK-886] results in increased expression of TNF protein] |
CTD |
PMID:19883121 PMID:22381257 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
EXP |
MK-886 inhibits the reaction [pirinixic acid results in increased expression of UCP2 mRNA]; MK-886 inhibits the reaction [pirinixic acid results in increased expression of UCP2 protein] |
CTD |
PMID:16782780 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
affects response to substance |
ISO |
ABCC1 gene SNP affects the susceptibility to montelukast |
CTD |
PMID:16293801 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
montelukast inhibits the reaction [ABCC2 protein results in increased export of calcein AM]; montelukast inhibits the reaction [ABCC2 protein results in increased export of Paclitaxel]; montelukast inhibits the reaction [ABCC2 protein results in increased export of Saquinavir] |
CTD |
PMID:19952419 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
montelukast inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein] |
CTD |
PMID:21381050 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Agt |
angiotensinogen |
affects response to substance |
ISO |
AGT polymorphism affects the susceptibility to montelukast |
CTD |
PMID:21624492 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
montelukast inhibits the reaction [Cisplatin results in decreased secretion of ALB protein]; montelukast inhibits the reaction [Prednisolone results in decreased secretion of ALB protein] |
CTD |
PMID:28902463 PMID:30276927 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
affects response to substance |
ISO |
ALOX5 gene SNP affects the susceptibility to montelukast |
CTD |
PMID:16293801 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
montelukast inhibits the reaction [Streptozocin results in increased expression of BAX protein] |
CTD |
PMID:27702591 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
montelukast inhibits the reaction [Streptozocin results in decreased expression of BCL2 protein] |
CTD |
PMID:27702591 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression |
ISO |
montelukast results in increased expression of BGLAP mRNA |
CTD |
PMID:19544365 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
ISO EXP |
montelukast results in increased expression of CASP3 protein montelukast inhibits the reaction [Cisplatin results in increased expression of CASP3 protein]; montelukast inhibits the reaction [Prednisolone results in increased expression of CASP3 protein]; montelukast inhibits the reaction [Rotenone results in increased activity of CASP3 protein] montelukast inhibits the reaction [Streptozocin results in increased expression of CASP3 protein modified form] |
CTD |
PMID:14633444 PMID:27702591 PMID:28902463 PMID:30222980 PMID:30276927 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
montelukast inhibits the reaction [Indomethacin results in increased activity of CAT protein]; montelukast inhibits the reaction [Prednisolone results in decreased activity of CAT protein] |
CTD |
PMID:17895592 PMID:30276927 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
montelukast inhibits the reaction [CCL2 protein results in increased abundance of Calcium] montelukast inhibits the reaction [Cisplatin results in increased expression of and results in increased secretion of CCL2 protein] |
CTD |
PMID:16771778 PMID:28902463 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
increases expression |
ISO |
montelukast results in increased expression of COL10A1 mRNA |
CTD |
PMID:19544365 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
increases expression |
ISO |
montelukast results in increased expression of COL2A1 mRNA |
CTD |
PMID:19544365 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
montelukast results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
montelukast results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases metabolic processing decreases activity |
ISO |
CYP2C8 protein results in increased metabolism of montelukast montelukast results in decreased activity of CYP2C8 protein |
CTD |
PMID:15601807 PMID:17994679 PMID:19309152 PMID:19328226 PMID:21336516 PMID:33253783 PMID:33775687 More...
|
|
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
multiple interactions decreases expression |
ISO EXP |
alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol inhibits the reaction [montelukast binds to and results in decreased activity of CYSLTR1 protein]; montelukast binds to and results in decreased activity of CYSLTR1 protein; montelukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; montelukast inhibits the reaction [[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; montelukast inhibits the reaction [[Uridine Diphosphate metabolite results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein]; montelukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; montelukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; montelukast inhibits the reaction [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein] montelukast inhibits the reaction [Rotenone results in increased expression of CYSLTR1 mRNA] montelukast inhibits the reaction [Streptozocin results in increased expression of CYSLTR1 mRNA]; montelukast inhibits the reaction [Streptozocin results in increased expression of CYSLTR1 protein] montelukast results in decreased expression of CYSLTR1 mRNA |
CTD |
PMID:9620942 PMID:10391245 PMID:10462554 PMID:10851239 PMID:11006272 PMID:11996896 PMID:12853847 PMID:14718577 PMID:18651869 PMID:19544365 PMID:20083671 PMID:27702591 PMID:30222980 More...
|
|
NCBI chr X:71,661,415...71,690,158
Ensembl chr X:71,663,821...71,690,121
|
|
G |
Cysltr2 |
cysteinyl leukotriene receptor 2 |
multiple interactions |
ISO |
montelukast binds to and results in decreased activity of CYSLTR2 protein; montelukast inhibits the reaction [Leukotriene D4 binds to CYSLTR2 protein] |
CTD |
PMID:10851239 |
|
NCBI chr15:48,190,251...48,229,906
Ensembl chr15:48,189,073...48,304,136
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
montelukast inhibits the reaction [Cisplatin results in increased secretion of EDN1 protein] |
CTD |
PMID:28902463 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
montelukast results in increased expression of FAS protein |
CTD |
PMID:14633444 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
multiple interactions |
ISO |
montelukast inhibits the reaction [Leukotriene D4 results in increased activity of GPR17 protein] |
CTD |
PMID:18974869 |
|
NCBI chr18:23,576,212...23,583,177
Ensembl chr18:23,577,242...23,582,966
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
montelukast inhibits the reaction [Cisplatin results in increased expression of HMOX1 protein] |
CTD |
PMID:28902463 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
montelukast inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:19118273 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
montelukast inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:19118273 |
|
NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
montelukast inhibits the reaction [Ovalbumin results in increased secretion of IL13 protein] |
CTD |
PMID:30696844 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
montelukast inhibits the reaction [Streptozocin results in increased expression of IL1B protein] montelukast inhibits the reaction [Rotenone results in increased expression of IL1B protein] |
CTD |
PMID:27702591 PMID:30222980 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
montelukast inhibits the reaction [Ovalbumin results in increased secretion of IL4 protein] |
CTD |
PMID:30696844 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
multiple interactions decreases expression |
ISO |
[montelukast co-treated with Cetirizine] results in decreased expression of IL5 protein; [montelukast co-treated with desloratadine] results in decreased expression of IL5 protein montelukast inhibits the reaction [Ovalbumin results in increased secretion of IL5 protein] montelukast results in decreased expression of IL5 mRNA |
CTD |
PMID:14619337 PMID:15061398 PMID:30696844 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
montelukast inhibits the reaction [Leukotriene D4 results in increased secretion of IL6 protein] |
CTD |
PMID:19118273 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lta4h |
leukotriene A4 hydrolase |
affects response to substance |
ISO |
LTA4H gene SNP affects the susceptibility to montelukast |
CTD |
PMID:16293801 |
|
NCBI chr 7:27,969,796...28,001,600
Ensembl chr 7:27,969,789...28,001,600
|
|
G |
Ltc4s |
leukotriene C4 synthase |
affects response to substance |
ISO |
LTC4S gene SNP affects the susceptibility to montelukast |
CTD |
PMID:16293801 |
|
NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
affects expression |
ISO |
montelukast affects the expression of MAPK1 protein modified form |
CTD |
PMID:18059327 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
affects expression |
ISO |
montelukast affects the expression of MAPK3 protein modified form |
CTD |
PMID:18059327 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
montelukast inhibits the reaction [Indomethacin results in increased activity of MPO protein]; montelukast inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:11698051 PMID:17895592 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
montelukast inhibits the reaction [Prednisolone results in increased expression of NOS2 protein]; montelukast inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of NOS2 protein] |
CTD |
PMID:11698051 PMID:30276927 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
increases activity |
ISO |
montelukast results in increased activity of NR1H4 protein |
CTD |
PMID:22414727 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Pon1 |
paraoxonase 1 |
decreases activity |
ISO |
montelukast results in decreased activity of PON1 protein |
CTD |
PMID:31581362 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
affects expression |
ISO |
montelukast affects the expression of PTGS2 protein |
CTD |
PMID:18059327 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
montelukast inhibits the reaction [Streptozocin results in increased expression of and affects the localization of RELA protein] montelukast inhibits the reaction [Rotenone results in increased expression of RELA protein] |
CTD |
PMID:27702591 PMID:30222980 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rnase3 |
ribonuclease A family member 3 |
decreases expression |
ISO |
montelukast results in decreased expression of RNASE3 protein |
CTD |
PMID:10588996 |
|
NCBI chr15:24,511,894...24,512,764
Ensembl chr15:24,511,891...24,512,790
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression |
ISO |
montelukast results in increased expression of RUNX2 mRNA |
CTD |
PMID:19544365 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
montelukast inhibits the reaction [Rotenone results in increased expression of TH protein] |
CTD |
PMID:30222980 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions affects expression |
ISO EXP |
montelukast inhibits the reaction [Leukotriene D4 results in increased secretion of TNF protein] montelukast inhibits the reaction [Cisplatin results in increased expression of and results in increased secretion of TNF protein]; montelukast inhibits the reaction [Rotenone results in increased expression of TNF protein] montelukast inhibits the reaction [Streptozocin results in increased expression of TNF protein] montelukast affects the expression of TNF protein |
CTD |
PMID:18059327 PMID:19118273 PMID:27702591 PMID:28902463 PMID:30222980 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
montelukast inhibits the reaction [Rotenone results in increased expression of TP53 mRNA] |
CTD |
PMID:30222980 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
EXP |
LY 171883 results in increased expression of BAD protein |
CTD |
PMID:12065618 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
LY 171883 results in increased expression of BAX protein |
CTD |
PMID:12065618 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
multiple interactions |
ISO |
[LY 171883 binds to and results in decreased activity of CYSLTR1 protein] which results in decreased abundance of Leukotriene B4; LY 171883 binds to and results in decreased activity of CYSLTR1 protein LY 171883 binds to and results in increased activity of CYSLTR1 protein; LY 171883 inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] |
CTD |
PMID:8014878 PMID:14718577 |
|
NCBI chr X:71,661,415...71,690,158
Ensembl chr X:71,663,821...71,690,121
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
LY 171883 binds to and results in increased activity of PPARA protein |
CTD |
PMID:15491415 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
LY 171883 results in increased activity of [PPARG protein co-treated with RXRA protein] |
CTD |
PMID:8700121 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
LY 171883 results in increased activity of [PPARG protein co-treated with RXRA protein] |
CTD |
PMID:8700121 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
zafirlukast results in decreased activity of ABCB11 protein |
CTD |
PMID:23956101 PMID:28437613 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
zafirlukast results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
zafirlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine] |
CTD |
PMID:15180633 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
increases expression |
ISO |
zafirlukast results in increased expression of BMP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Cat |
catalase |
increases expression |
EXP |
zafirlukast results in increased expression of CAT protein |
CTD |
PMID:12962976 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
zafirlukast results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
zafirlukast inhibits the reaction [CYP1A2 protein results in increased metabolism of Theophylline] |
CTD |
PMID:9701106 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
zafirlukast results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions decreases activity |
ISO |
zafirlukast inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] zafirlukast results in decreased activity of CYP2C19 protein |
CTD |
PMID:15370959 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
zafirlukast results in decreased activity of CYP2C8 protein |
CTD |
PMID:15601807 |
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity multiple interactions increases metabolic processing |
ISO |
zafirlukast metabolite results in decreased activity of CYP3A4 protein; zafirlukast results in decreased activity of CYP3A4 protein zafirlukast inhibits the reaction [CYP3A4 protein results in increased metabolism of Midazolam] CYP3A4 protein results in increased metabolism of zafirlukast |
CTD |
PMID:15370959 PMID:16167835 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
multiple interactions affects binding |
ISO |
[zafirlukast binds to and results in decreased activity of CYSLTR1 protein] which affects the abundance of Calcium; alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol inhibits the reaction [zafirlukast binds to and results in decreased activity of CYSLTR1 protein]; zafirlukast binds to and results in decreased activity of CYSLTR1 protein; zafirlukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein]; zafirlukast inhibits the reaction [[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; zafirlukast inhibits the reaction [[Uridine Diphosphate metabolite results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein]; zafirlukast inhibits the reaction [CYSLTR1 protein promotes the reaction [Leukotriene D4 results in increased abundance of Calcium]]; zafirlukast inhibits the reaction [CYSLTR1 protein results in increased susceptibility to Leukotriene D4]; zafirlukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; zafirlukast inhibits the reaction [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein] zafirlukast binds to and results in decreased activity of CYSLTR1 protein; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein] zafirlukast binds to CYSLTR1 protein |
CTD |
PMID:1554195 PMID:8014876 PMID:8384568 PMID:8389103 PMID:8389105 PMID:9152370 PMID:9620942 PMID:9647482 PMID:10391245 PMID:10462554 PMID:10509933 PMID:10825389 PMID:10851239 PMID:11006272 PMID:11061985 PMID:11705452 PMID:11996896 PMID:12853847 PMID:14718577 PMID:15990778 PMID:18651869 PMID:18704935 PMID:20083671 More...
|
|
NCBI chr X:71,661,415...71,690,158
Ensembl chr X:71,663,821...71,690,121
|
|
G |
Cysltr2 |
cysteinyl leukotriene receptor 2 |
multiple interactions |
ISO |
zafirlukast binds to and results in decreased activity of CYSLTR2 protein; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR2 protein] |
CTD |
PMID:10851239 |
|
NCBI chr15:48,190,251...48,229,906
Ensembl chr15:48,189,073...48,304,136
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions decreases expression |
ISO |
zafirlukast inhibits the reaction [Leukotriene C4 results in increased expression of EDN1 mRNA]; zafirlukast inhibits the reaction [Leukotriene C4 results in increased expression of EDN1 protein] zafirlukast results in decreased expression of EDN1 protein |
CTD |
PMID:11372388 PMID:12781059 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
zafirlukast results in increased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[zafirlukast co-treated with Prednisone co-treated with Budesonide] inhibits the reaction [Antigens results in increased secretion of IFNG protein] |
CTD |
PMID:16160912 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
zafirlukast results in decreased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
zafirlukast results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein] |
CTD |
PMID:18704935 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
increases expression |
ISO |
zafirlukast results in increased expression of MET mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP2 mRNA]; zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP2 protein] |
CTD |
PMID:31816286 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP9 mRNA]; zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP9 protein] |
CTD |
PMID:31816286 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
decreases activity decreases expression |
EXP |
zafirlukast results in decreased activity of MPO protein zafirlukast results in decreased expression of MPO protein |
CTD |
PMID:11438310 PMID:12962976 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of OCLN mRNA]; zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of OCLN protein] |
CTD |
PMID:31816286 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
zafirlukast results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
zafirlukast results in increased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rnase3 |
ribonuclease A family member 3 |
decreases expression |
ISO |
zafirlukast results in decreased expression of RNASE3 protein |
CTD |
PMID:15612964 |
|
NCBI chr15:24,511,894...24,512,764
Ensembl chr15:24,511,891...24,512,790
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
zafirlukast inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
zafirlukast inhibits the reaction [SLC47A1 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
zafirlukast inhibits the reaction [SLC47A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
decreases expression |
ISO |
zafirlukast results in decreased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
zafirlukast results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of TJP1 mRNA]; zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of TJP1 protein] |
CTD |
PMID:31816286 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein] |
CTD |
PMID:18704935 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
decreases expression |
ISO |
zafirlukast results in decreased expression of TNFAIP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
affects response to substance |
ISO |
ABCC1 gene SNP affects the susceptibility to zileuton |
CTD |
PMID:19214143 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
zileuton inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ACTA2 protein] |
CTD |
PMID:27697457 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
zileuton metabolite binds to and results in increased alkylation of ALB protein |
CTD |
PMID:17944539 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
affects response to substance decreases expression multiple interactions decreases activity |
ISO EXP |
ALOX5 gene SNP affects the susceptibility to zileuton zileuton results in decreased expression of ALOX5 mRNA [[zileuton co-treated with Calcimycin] results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Leukotriene B4]; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Indomethacin results in increased abundance of Leukotriene B4]; [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; zileuton binds to and results in decreased activity of ALOX5 protein; zileuton inhibits the reaction [ALOX5 protein affects the abundance of lipoxin A4]; zileuton inhibits the reaction [IL13 protein results in increased expression of ALOX5 mRNA]; zileuton inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased activity of ALOX5 protein]; zileuton inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of ALOX5 protein]; zileuton inhibits the reaction [Peroxynitrous Acid results in increased nitrosation of ALOX5 protein] [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [zileuton results in decreased activity of ALOX5 protein] which results in decreased expression of NOS1; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene B4]]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene C4]]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene D4]]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene E4]]; zileuton inhibits the reaction [Ovalbumin results in increased expression of ALOX5 mRNA] [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Platelet Activating Factor]; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Leukotriene C4]; [zileuton results in decreased activity of ALOX5 protein] which affects the abundance of Arachidonic Acid; [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene C4; [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene D4; [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene E4; [zileuton results in decreased activity of ALOX5 protein] which results in decreased susceptibility to Arachidonic Acid; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased abundance of Leukotriene B4]]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]]; zileuton inhibits the reaction [ALOX5 protein results in increased metabolism of Arachidonic Acid]; zileuton inhibits the reaction [ALOX5 protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]]; zileuton inhibits the reaction [L 708714 binds to ALOX5 protein] |
CTD |
PMID:1781415 PMID:7577949 PMID:7592874 PMID:7665580 PMID:7812673 PMID:7922131 PMID:7929400 PMID:7990266 PMID:8058773 PMID:8111568 PMID:8113982 PMID:8186192 PMID:8387780 PMID:8621850 PMID:8666909 PMID:9113110 PMID:9223651 PMID:9445378 PMID:9495842 PMID:9593866 PMID:9599246 PMID:9609743 PMID:9850156 PMID:10377029 PMID:10694244 PMID:10698703 PMID:10764316 PMID:10852428 PMID:11286996 PMID:11529688 PMID:11561080 PMID:11694324 PMID:11886531 PMID:12388339 PMID:12629151 PMID:12649539 PMID:12654629 PMID:12794006 PMID:14726295 PMID:15266012 PMID:15326064 PMID:15328337 PMID:15501964 PMID:15935457 PMID:17113579 PMID:18295198 PMID:18475545 PMID:19214143 PMID:19309543 More...
|
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
Palmitic Acid promotes the reaction [zileuton results in increased activity of CASP3 protein] |
CTD |
PMID:22700542 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity |
ISO |
Palmitic Acid promotes the reaction [zileuton results in increased activity of CASP7 protein] |
CTD |
PMID:22700542 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions |
ISO |
zileuton inhibits the reaction [Ovalbumin results in increased expression of CCL11 mRNA] |
CTD |
PMID:12794006 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl12 |
C-C motif chemokine ligand 12 |
multiple interactions |
ISO |
zileuton inhibits the reaction [CCL12 protein results in increased abundance of Leukotriene B4]; zileuton inhibits the reaction [Ovalbumin results in increased expression of CCL12 mRNA] |
CTD |
PMID:12388339 PMID:12794006 |
|
NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
zileuton inhibits the reaction [CCL2 protein results in increased abundance of Leukotriene B4]; zileuton inhibits the reaction [Ovalbumin results in increased expression of CCL2 mRNA] |
CTD |
PMID:12388339 PMID:12794006 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
increases expression |
ISO |
zileuton results in increased expression of COL10A1 mRNA |
CTD |
PMID:19544365 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
increases expression |
ISO |
zileuton results in increased expression of COL2A1 mRNA |
CTD |
PMID:19544365 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
zileuton inhibits the reaction [CXCL1 protein results in increased abundance of Leukotriene B4] |
CTD |
PMID:12388339 |
|
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity |
EXP |
zileuton results in increased activity of CYP1A1 protein |
CTD |
PMID:11509739 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases activity |
ISO |
zileuton inhibits the reaction [CYP1A2 protein results in increased metabolism of Phenacetin] zileuton results in decreased activity of CYP1A2 protein |
CTD |
PMID:14570767 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression |
EXP |
zileuton results in increased expression of CYP2B2 mRNA |
CTD |
PMID:12883083 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
zileuton results in decreased activity of CYP3A4 protein |
CTD |
PMID:15482930 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
decreases expression |
EXP |
zileuton results in decreased expression of DDIT3 mRNA |
CTD |
PMID:12883083 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Epx |
eosinophil peroxidase |
multiple interactions |
ISO |
zileuton inhibits the reaction [Ovalbumin results in increased expression of EPX protein] |
CTD |
PMID:12794006 |
|
NCBI chr10:72,666,865...72,677,952
Ensembl chr10:72,666,865...72,677,952
|
|
G |
Fth1 |
ferritin heavy chain 1 |
decreases expression |
EXP |
zileuton results in decreased expression of FTH1 mRNA |
CTD |
PMID:12883083 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Hdac1 |
histone deacetylase 1 |
decreases expression |
EXP |
zileuton results in decreased expression of HDAC1 mRNA |
CTD |
PMID:12883083 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
decreases expression |
EXP |
zileuton results in decreased expression of HMGCS1 mRNA |
CTD |
PMID:12883083 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
increases activity |
ISO |
zileuton results in increased activity of HSD11B2 protein |
CTD |
PMID:10377029 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
affects expression multiple interactions |
ISO |
zileuton affects the expression of ICAM1 protein zileuton inhibits the reaction [dinitrobenzenesulfonic acid results in increased expression of ICAM1 protein] |
CTD |
PMID:15266012 PMID:15821759 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
zileuton inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:19118273 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
zileuton inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:19118273 |
|
NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13 |
interleukin 13 |
affects expression multiple interactions |
ISO EXP |
zileuton affects the expression of IL13 protein zileuton inhibits the reaction [Ovalbumin results in increased expression of IL13 mRNA] zileuton inhibits the reaction [IL13 protein results in increased abundance of Leukotriene B4]; zileuton inhibits the reaction [IL13 protein results in increased expression of ALOX5 mRNA]; zileuton inhibits the reaction [IL13 protein results in increased expression of MUC5AC mRNA]; zileuton inhibits the reaction [IL13 protein results in increased expression of MUC5AC protein] |
CTD |
PMID:12654629 PMID:12794006 PMID:15927844 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
zileuton inhibits the reaction [Bleomycin results in increased expression of IL1B protein] |
CTD |
PMID:17118201 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
zileuton inhibits the reaction [Ovalbumin results in increased expression of IL4 mRNA] |
CTD |
PMID:12794006 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases secretion |
ISO |
zileuton inhibits the reaction [Endotoxins results in increased expression of IL6 protein]; zileuton inhibits the reaction [Leukotriene D4 results in increased secretion of IL6 protein] zileuton results in decreased secretion of IL6 protein |
CTD |
PMID:7496871 PMID:19118273 PMID:20436887 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
zileuton inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAM protein] |
CTD |
PMID:15328337 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
affects expression |
ISO |
zileuton affects the expression of MAPK1 protein modified form |
CTD |
PMID:18059327 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
affects expression decreases expression |
ISO EXP |
zileuton affects the expression of MAPK3 protein modified form zileuton results in decreased expression of MAPK3 mRNA |
CTD |
PMID:12883083 PMID:18059327 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases activity |
EXP |
zileuton results in decreased activity of MGST1 protein |
CTD |
PMID:9890956 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity decreases expression |
EXP |
zileuton results in decreased activity of MMP9 protein zileuton results in decreased expression of MMP9 mRNA |
CTD |
PMID:19309543 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions decreases activity |
ISO EXP |
zileuton inhibits the reaction [Bleomycin results in increased activity of MPO protein]; zileuton inhibits the reaction [dinitrobenzenesulfonic acid results in increased activity of MPO protein]; zileuton inhibits the reaction [Ovalbumin results in increased expression of MPO protein]; zileuton inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MPO protein] zileuton results in decreased activity of MPO protein zileuton inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; zileuton inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:7812673 PMID:11698051 PMID:12794006 PMID:15339030 PMID:15821759 PMID:17118201 More...
|
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO EXP |
zileuton inhibits the reaction [Ovalbumin results in increased expression of MUC5AC mRNA]; zileuton inhibits the reaction [Ovalbumin results in increased expression of MUC5AC protein] zileuton inhibits the reaction [IL13 protein results in increased expression of MUC5AC mRNA]; zileuton inhibits the reaction [IL13 protein results in increased expression of MUC5AC protein] |
CTD |
PMID:12654629 PMID:12794006 |
|
NCBI chr 1:196,864,375...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions |
ISO |
[zileuton results in decreased activity of ALOX5 protein] which results in decreased expression of NOS1 |
CTD |
PMID:11694324 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
zileuton inhibits the reaction [dinitrobenzenesulfonic acid affects the localization of OCLN protein] |
CTD |
PMID:16670640 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Ptafr |
platelet-activating factor receptor |
multiple interactions |
ISO |
zileuton binds to and results in decreased activity of PTAFR protein; zileuton inhibits the reaction [Platelet Activating Factor binds to PTAFR protein] |
CTD |
PMID:11529688 |
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
affects expression multiple interactions |
ISO |
zileuton affects the expression of PTGS2 protein zileuton inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:18059327 PMID:28487374 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rplp0 |
ribosomal protein lateral stalk subunit P0 |
decreases expression |
EXP |
zileuton results in decreased expression of RPLP0 mRNA |
CTD |
PMID:12883083 |
|
NCBI chr12:41,054,363...41,057,632
Ensembl chr12:41,054,179...41,057,632
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
zileuton inhibits the reaction [dinitrobenzenesulfonic acid results in increased expression of SELE protein] |
CTD |
PMID:15821759 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Selp |
selectin P |
multiple interactions |
ISO |
zileuton inhibits the reaction [dinitrobenzenesulfonic acid results in increased expression of SELP protein] zileuton inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein] |
CTD |
PMID:11116075 PMID:15821759 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
increases expression |
ISO |
zileuton results in increased expression of SOX9 mRNA |
CTD |
PMID:19544365 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
zileuton inhibits the reaction [dinitrobenzenesulfonic acid affects the localization of TJP1 protein] |
CTD |
PMID:16670640 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tnf |
tumor necrosis factor |
affects expression multiple interactions |
ISO |
zileuton affects the expression of TNF protein zileuton inhibits the reaction [Bleomycin results in increased expression of TNF protein] zileuton inhibits the reaction [Endotoxins results in increased expression of TNF protein]; zileuton inhibits the reaction [Leukotriene D4 results in increased secretion of TNF protein] |
CTD |
PMID:7496871 PMID:17118201 PMID:18059327 PMID:19118273 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
zileuton inhibits the reaction [dinitrobenzenesulfonic acid results in increased expression of VCAM1 protein] |
CTD |
PMID:15821759 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|